PEDIATRIC AND HERITABLE DISORDERS: Edited by Polly J. FergusonUpdate on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible?Klein-Wieringa, Inge R.a; Brinkman, Danielle M.C.b; ten Cate, Rebeccab; Hissink Muller, Petra C.E.b Author Information aDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands bDepartment of Paediatrics/Paediatric Rheumatology, Leiden, The Netherlands Correspondence to Petra C.E. Hissink Muller, MD, PhD, Department of Paediatrics, J6-S, LUMC, PO Box 9600, 2300 RC Leiden, the Netherlands. Tel: +31 715264131; fax: +31 715248198; e-mail: [email protected] Current Opinion in Rheumatology: September 2020 - Volume 32 - Issue 5 - p 403-413 doi: 10.1097/BOR.0000000000000727 Buy Metrics Abstract Purpose of review This review concerns the outcome for nonsystemic juvenile idiopathic arthritis (JIA) with emphasis on treatment-to-target (T2T) and treatment strategies aiming at inactive disease by giving an overview of recent articles. Recent findings More efficacious therapies and treatment strategies/T2T with inactive disease as target, have improved the outcome for JIA significantly. Recent studies regarding treatment strategies have shown 47–68% inactive disease after 1 year. Moreover, probability of attaining inactive disease at least once in the first year seems even higher in recent cohort-studies, reaching 80%, although these studies included relatively high numbers of oligoarticular JIA patients. However, 26–76% of patients flare upon therapy withdrawal and prediction of flares is still difficult. Summary Remission can be achieved and sustained in (some) JIA patients, regardless of initial treatment. Cornerstone principles in the management of nonsystemic JIA treatment are early start of DMARD therapy, striving for inactive disease and T2T by close and repeated monitoring of disease activity. T2T and tight control appear to be more important than a specific drug in JIA. Next to inactive disease, it is important that patients/parents are involved in personal targets, like reduction of pain and fatigue. Future studies should focus on predictors (based on imaging-methods or biomarkers) for sustained drug-free remission and flare. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.